Core Viewpoint - Harvard Bioscience, Inc. has announced a 1-for-10 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective March 13, 2026, with trading on a post-split basis starting March 16, 2026 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 10 shares of common stock into 1 share, resulting in a reduction of outstanding shares from approximately 44.7 million to about 4.5 million [3][4]. - No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment based on the adjusted closing price [3]. - The total authorized number of shares will remain unchanged, and proportional adjustments will be made to stock options, warrants, and convertible securities [4]. Group 2: Stockholder Actions - Stockholders holding shares electronically will not need to take any action to receive post-split shares, while those with physical certificates will receive instructions for exchanging them [5]. - Stockholders with shares held through brokers will have their positions automatically adjusted without needing to take action [5]. Group 3: Company Overview - Harvard Bioscience is a leading developer and manufacturer of life science research tools, serving a diverse customer base including academic institutions and pharmaceutical companies [7].

Core Viewpoint - Harvard Bioscience, Inc. announced preliminary financial results for Q4 2025 and outlined a long-term strategy aimed at sustainable growth and increasing shareholder value [1][2]. Financial Highlights - The company expects to report Q4 revenue of $23.7 million, which is above the midpoint of the guidance range of $22.5 million to $24.5 million [6]. - Gross margin is projected at 60%, at the high end of the guidance range of 58% to 60%, attributed to a better mix of higher-margin products and prior cost reductions [6]. - Adjusted EBITDA is anticipated to be $3.8 million, reflecting a 27% year-over-year growth driven by cost reductions and improved expense management [6]. Strategic Focus - The company is transitioning from a traditional tools provider to a leader in Translational Science, aiming to bridge the gap between laboratory research and human clinical success [2]. - The strategy is built around four pillars: leading the translational bridge, new product introduction pipeline, consumables revenue expansion, and operational excellence [7]. - The focus on consumables aims to increase the recurring revenue mix from the current 55% of total revenues [7]. Management Commentary - The CEO expressed satisfaction with the fourth quarter performance and confidence in driving year-over-year revenue growth and mid-to-high single-digit adjusted EBITDA growth in 2026 [3][5]. Upcoming Events - The full Q4 and fiscal year 2025 results will be released on March 12, 2026, followed by a conference call to discuss the results and strategy in detail [5][8].